The Protein Biomarkers of Feline Mammary Carcinoma

Abstract

Feline mammary carcinoma (FMC) is a prevalent aggressive malignancy in cats, characterized by a poor prognosis and limited treatment options beyond mastectomy. This review explores the significance of various protein biomarkers, including HER2, BCL-2, RON, Ki 67, and COX-2, in diagnosing and treating FMC in cats. Early diagnosis and treatment due to the aggressive nature of FMC is important, which often leads to limited therapeutic options and poor responses in later stages. Biomarkers play a crucial role in improving diagnostic accuracy, guiding therapeutic decisions, and monitoring disease progression in cats with FMC. The review highlights the potential of biomarkers to revolutionize diagnostic approaches in veterinary clinics, offering a more targeted and effective strategy for managing feline mammary carcinomas.